Glycogen Storage Disease Type 2
3
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Neutralizing Antibody To Spk3006 Capsid
Related Conditions
Often studied with 7 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica-
Research Network
Common Treatments
- Neutralizing Antibody To Spk3006 Capsid1
- Spk30061
Active Sponsors
- Spark Therapeutics, Inc.2
- University of Aarhus1
Top Investigators
University of California Irvine Health
Aarhus University Hospital
Related Conditions
- Lysosomal Storage Diseases2
- Acid Maltase Deficiency2
- Lopd2
- Pompe Disease2
- Pompe Disease Lateonset2